Menu
  • Join
  • Login
  • Contact
 

Search abstracts


A systematic review of dementia and cognitive impairment risk with proton pump inhibitor therapy

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: GILMARTIN-THOMAS, Julia (School of Public Health and Preventive Medicine, Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia)
  • Co-author(s): Riley Batchelor: Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
    Julia Fiona-Maree Gilmartin: Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia;Research Department of Practice and Policy, University College London School of Pharmacy, London, United Kingdom
    William Kemp: Department of Gastroenterology, Alfred Health, Melbourne, Australia
    Ingrid Hopper: Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
    Danny Liew : Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
  • Abstract:

    Backgrounds

    Proton pump inhibitors (PPIs) are among the most widely used medications worldwide. Recent studies have suggested an increased risk of cognitive impairment and dementia diagnosis in people who consume PPIs.

    Aims

    This systematic review aims to explore the use of PPIs and acute cognitive impairment and dementia.

    Methods

    Systematic

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses